Skip to main content

Table 1 Characteristics of 128 patients with sustained viral suppression after 4 years of antiretroviral therapy at the Infectious Diseases Institute research cohort

From: Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort

Median CD4 increase ϕ median (range) cells/μl

Suboptimal CD4 responders (n=39) 165 (-43-298);]

Optimal CD4 reconstitution (n=48) 528 (Range 417-878)

P value*

Age (yrs) [median (IQR)]

37 (31-42)

35 (31-43)

0.875

Female gender [n (%)]

28 (72)

22 (46)

0.062

Baseline CD4 count cells/μl [median (IQR)]¥

78 (2-117)

115 (97-185)

0.018

<100 cells/μl [n(%)]

26 (67)

7 (15)

0.0015

Current CD4 cells/μl [median (IQR)]

214 (190-282)

474 (438-645)

<0.001

BMI [median (IQR)]

22 (20-25)

26 (22-28)

0.162

Hemoglobin [median (IQR)]

14 (12-15)

14 (13-15)

0.481

Hepatitis B positive [n]

2

1

0.911

First-line HAART regimen∞

   

D4T-3TC-NVP/EFZ [n (%)]

12 (31)

27 (56)

 

ZDV-3TC-NVP/EFZ [n (%)]

25 (64)

17 (35)

 

TDF-3TC-NVP/EFZ [n (%)]

2 (5)

4 (8)

0.340

  1. * Chi square test was used for categorical variables and Kruskal-Wallis test was used for the continuous variables.
  2. ϕThe magnitude of CD4 increase from the baseline counts was grouped into 4 quartiles; ‘Suboptimal responders’ were patients within the lowest quartile and ‘Optimal responders’ were individuals within the highest quartile of CD4 increase.
  3. ¥All patients initiated antiretroviral therapy at CD4 200 cells/μl and below.
  4. ∞ Study participants were all on their initial first-line regimen given that they had sustained viral suppression